Zusammenfassung
Eine Impfung gegen humane Papillomaviren bietet die einzigartige Möglichkeit, die Manifestation der HPV-bedingten Präkanzerosen vollständig zu verhindern. Sie wird aber die sekundäre Prävention, zu der Zytologie und Kolposkopie gehören, auf absehbare Zeit nicht überflüssig machen. Vielmehr ergeben sich neue Herausforderungen für diese etablierten Verfahren.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Albring C, Harlfinger W (2007) Kompetenz und Vertrauen stärken (Editorial). Frauenarzt 48:417
Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ (2013) Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 346: f 2032
Bharadwaj M, Hussain S, Nasare V, Das BC (2009) HPV & HPV vaccination: issues in developing countries. Indian J Med Res 130:327–333
Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM (2011) Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 377: 2085 –2092
Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A (2011) End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Brit J Cancer 105: 28–37
Daayana S, Elkord E, Winters U, Pawlita M, Roden R, Stern PL, Kitchener HC (2010) Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Brit J Cancer 102: 1129 –1136
de Sanjose S, Quint WG, Alemany L et al. (2010) Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 11: 1048– 1056
Einstein MH, Baron M, Levin MJ, Chatterjee A, Edwards RP, Zepp F, Carletti I, Dessy FJ, Trofa AF, Schuind A, Dubin G (2009) Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5:705–719
FUTURE II Study Group (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 356: 1915–1927
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356: 1928–1943
Garnett GP, Waddell HC (2000) Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 19:101–111
Gross G, Gissmann L, Hillemanns P, Ikenberg H, Kaufmann AM, Petry KU, Pfister H, Schneede P, Schneider A, Smola S (2010) Die Impfprävention HPV-assoziierter Neoplasien – eine Zusammenfassung der deutschen S3-Leitlinie. Deutsche Medizinische Wochenschrift 135: 1083 –1086
Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743–753
Hillemanns P (2013) HPV-Impfstoff der zweiten Generation gegen neun Virustypen gerichtet. Deutsches Ärzteblatt 110:2479–2480
Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM (2012) Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 344:e1401
Kang WD, Choi HS, Kim SM (2013) Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol 130(2):264–268
Kaufmann AM, Nieland JD, Jochmus I et al. (2007) Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3). Int J Cancer 121: 2794 –2800
Kling M, Zeichner JA (2010) The role of the human papillomavirus (HPV) vaccine in developing countries. Int J Dermatol 49:377–379
Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, Gonzalez P, Solomon D, Jimenez S, Schiller JT, Lowy DR, Quint W, Sherman ME, Schussler J, Wacholder S (2011) Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 103: 1444 –1451
Lehtinen M, Paavonen J, Wheeler CM et al. (2012) Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 13:89–99
Naud P, Roteli-Martins CM, De Carvalho N (2011) HPV-16/18 vaccine: sustained immunogenicity and efficacy to 9.4 years. Abstract No O-1804. 27th International Papillomavirus Conference, 17.–22. Sept. 2011, Berlin
Paavonen J, Jenkins D, Bosch FX et al. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369: 2161 –2170
Read TR, Hocking JS, Chen MY, Donovan B, Bradshaw CS, Fairley CK (2011) The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sexually transmitted infections 87: 544–547
Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D (2012) Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 8:390–397
Schneider A, Hammerschmidt T, Schwarz TF, Rogoza RM, Ferko N, Siebert U (2007) Langfristige Public-Health-Effekte einer Impfung gegen Zervixkarzinom in Deutschland. Geburtsh Frauenheilk 67:850–858
Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjose S (2012) Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 7:38
Stanley M (2012) Perspective: Vaccinate boys too. Nature 488 : S10
Strasser T (1978) Reflections on cardiovascular diseases. Interdisciplinary Science Review 3:225–230
Sutton I, Lahoria R, Tan I, Clouston P, Barnett M (2009) CNS demyelination and quadrivalent HPV vaccination. Mult Scler 15:116–119
Wheeler CM, Kjaer SK, Sigurdsson K et al. (2009) The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 199:936–944
Wick DA, Webb JRA (2011) novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors. Vaccine 29: 7857 – 7866
zur Hausen H (2009) Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384:260–265
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Lellé, R., Küppers, V. (2014). HPV-Impfung. In: Kolposkopie in der Praxis. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38308-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-38308-3_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-38307-6
Online ISBN: 978-3-642-38308-3
eBook Packages: Medicine (German Language)